Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IsKia trial of isatuximab plus KRd versus KRd in transplant-eligible newly diagnosed multiple myeloma
NL-OMON54962Phase 3Recruiting
- Sponsor
- European Myeloma Network
- Start
- Jan 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab, carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network. Primary endpoint: Minimal residual disease negativity after post-ASCT consolidation by next-generation sequencing. Started Jan 2021; status: recruiting.
02
Drugs
isatuximabcarfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON54962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54962.